Polymicrobial infection in cystic fibrosis and future perspectives for improving Mycobacterium abscessus drug discovery

Emily, J. Baker; Gemma Allcott; Jonathan A. G. Cox

doi:10.1038/s44259-024-00060-5

Polymicrobial infection in cystic fibrosis and future perspectives for improving Mycobacterium abscessus drug discovery

Emily, J. Baker
, Gemma Allcott
, Jonathan A. G. Cox^*

^*Corresponding author for this work

School of Biosciences

Research output: Contribution to journal › Review article › peer-review

10 Downloads (Pure)

Abstract

Polymicrobial communities inhabit the cystic fibrosis (CF) airway, whereby microbial interactions can occur. One prominent CF pathogen is Mycobacterium abscessus, whose treatment is largely unsuccessful. This creates a need to discover novel antimicrobial agents to treat M. abscessus, however the methods used within antibiotic discovery are typically monomicrobial. This review will discuss this pathogen whilst considering the CF polymicrobial environment, to highlight future perspectives to improve M. abscessus drug discovery.

Original language	English
Article number	38
Number of pages	12
Journal	npj Antimicrobials and Resistance
Volume	2
Issue number	1
Early online date	14 Nov 2024
DOIs	https://doi.org/10.1038/s44259-024-00060-5
Publication status	Published - 14 Nov 2024

Bibliographical note

Copyright © The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

Funding

This research was funded by the Engineering and Physical Sciences Research Council (EPSRC) and Science Foundation Ireland (SFI) Centre for Doctoral Training in Engineered Tissues for Discovery, Industry and Medicine [EP/S02347X/1]. EJB is supported by a PhD Studentship funded by LifETIME CDT (EPSRC and SFI). GA is supported by a co-funded PhD studentship between Aston University and Comvita, NZ. The funders had no role in study design, data collection, analysis, decision to publish, or writing of the manuscript.

Access to Document

10.1038/s44259-024-00060-5Licence: CC BY 4.0

Polymicrobial infection in cystic fibrosis and future perspectives for improving Mycobacterium abscessus drug discovery
Copyright © The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/
Final published version, 2.09 MBLicence: CC BY 4.0

Cite this

@article{ed705b06ee3142538fb6319cfc5c12ec,

title = "Polymicrobial infection in cystic fibrosis and future perspectives for improving Mycobacterium abscessus drug discovery",

abstract = "Polymicrobial communities inhabit the cystic fibrosis (CF) airway, whereby microbial interactions can occur. One prominent CF pathogen is Mycobacterium abscessus, whose treatment is largely unsuccessful. This creates a need to discover novel antimicrobial agents to treat M. abscessus, however the methods used within antibiotic discovery are typically monomicrobial. This review will discuss this pathogen whilst considering the CF polymicrobial environment, to highlight future perspectives to improve M. abscessus drug discovery.",

author = "Baker, \{Emily, J.\} and Gemma Allcott and Cox, \{Jonathan A. G.\}",

note = "Copyright {\textcopyright} The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article{\textquoteright}s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article{\textquoteright}s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/",

year = "2024",

month = nov,

day = "14",

doi = "10.1038/s44259-024-00060-5",

language = "English",

volume = "2",

journal = "npj Antimicrobials and Resistance",

issn = "2731-8745",

number = "1",

}

TY - JOUR

T1 - Polymicrobial infection in cystic fibrosis and future perspectives for improving Mycobacterium abscessus drug discovery

AU - Baker, Emily, J.

AU - Allcott, Gemma

AU - Cox, Jonathan A. G.

N1 - Copyright © The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

PY - 2024/11/14

Y1 - 2024/11/14

N2 - Polymicrobial communities inhabit the cystic fibrosis (CF) airway, whereby microbial interactions can occur. One prominent CF pathogen is Mycobacterium abscessus, whose treatment is largely unsuccessful. This creates a need to discover novel antimicrobial agents to treat M. abscessus, however the methods used within antibiotic discovery are typically monomicrobial. This review will discuss this pathogen whilst considering the CF polymicrobial environment, to highlight future perspectives to improve M. abscessus drug discovery.

AB - Polymicrobial communities inhabit the cystic fibrosis (CF) airway, whereby microbial interactions can occur. One prominent CF pathogen is Mycobacterium abscessus, whose treatment is largely unsuccessful. This creates a need to discover novel antimicrobial agents to treat M. abscessus, however the methods used within antibiotic discovery are typically monomicrobial. This review will discuss this pathogen whilst considering the CF polymicrobial environment, to highlight future perspectives to improve M. abscessus drug discovery.

UR - https://www.nature.com/articles/s44259-024-00060-5

U2 - 10.1038/s44259-024-00060-5

DO - 10.1038/s44259-024-00060-5

M3 - Review article

SN - 2731-8745

VL - 2

JO - npj Antimicrobials and Resistance

JF - npj Antimicrobials and Resistance

IS - 1

M1 - 38

ER -

Polymicrobial infection in cystic fibrosis and future perspectives for improving Mycobacterium abscessus drug discovery

Abstract

Bibliographical note

Funding

Access to Document

Other files and links

Fingerprint

Cite this